Imunon, Inc. (formerly Celsion Corporation) — 2021 Form 10-K
Issuer and period: The supplied filing is Celsion Corporation’s annual report for the year ended December 31, 2021, filed March 31, 2022, under ticker CLSN. The request identifies Imunon, Inc.; the filing itself identifies Celsion, so investors should verify the issuer and any subsequent name change. Figures below reflect the filing’s 15-for-1 reverse-split restatement where applicable.
Business context and financial performance
Celsion was a clinical-stage biotechnology company with no commercial product sales. Its main clinical program was GEN-1, a DNA-based IL-12 immunotherapy in Phase II development for advanced ovarian cancer. ThermoDox, a heat-activated liposomal doxorubicin product, remained in investigator-sponsored studies after the company discontinued its Phase III OPTIMA liver-cancer study. PLACCINE, a DNA vaccine platform, was at a preclinical stage.
| Metric | 2021 | 2020 |
|---|---|---|
| Technology development and licensing revenue | $0.5 million | $0.5 million |
| Research and development expense | $10.6 million | $11.3 million |
| General and administrative expense | $10.9 million | $7.6 million |
| Operating loss | $21.0 million | $18.5 million |
| Net loss | $20.8 million | $21.5 million |
| Basic and diluted loss per share | $3.83 | $10.08 |
| Net cash used in operating activities | $16.2 million | $15.6 million |
Revenue was the scheduled amortization of a prior Hisun technology-transfer payment, not product sales. Operating expenses exceeded revenue substantially; conventional gross-margin measures are not meaningful for this development-stage business. The lower reported loss per share in 2021 reflects a higher weighted-average share count as well as the net loss.
Liquidity, debt and cash flow
- At year-end, current assets were $51.9 million, current liabilities $6.8 million and working capital $45.1 million. Balance-sheet cash and cash equivalents were $19.6 million; available-for-sale debt investments were $29.8 million; and $6.0 million was restricted as loan collateral.
- Management reported $56.9 million of cash, investments, interest receivable, NOL-sale proceeds and restricted cash, and estimated resources would fund operations through the end of 2024. This is management’s estimate, not a guarantee; the company also said it would need significant additional capital to advance candidates toward approval and commercialization.
- Operating cash use was $16.2 million. Financing provided $54.8 million, primarily from equity offerings; investing used $30.1 million, largely reflecting purchases of debt securities.
- The company drew $6.0 million under a $10.0 million Silicon Valley Bank facility in June 2021 to repay Horizon; the remaining $4.0 million was available to draw subject to facility terms. The SVB loan was prime-based, with interest-only payments for 24 months followed by amortization. A $6.0 million restricted deposit secured the facility. Year-end notes payable had a $5.9 million net carrying value.
Material changes and unusual items
- G&A rose $3.2 million, including higher stock compensation, professional fees—largely legal costs associated with litigation following the OPTIMA results—and directors’ and officers’ insurance. R&D fell $0.7 million; GEN-1 and PLACCINE development costs increased while ThermoDox-related costs declined.
- The company recorded a $2.0 million non-cash goodwill impairment in the fourth quarter of 2021, citing biotech-sector market-capitalization declines. Its $13.4 million ovarian-cancer IPR&D asset was not impaired. In 2020, it wrote off $2.4 million of GBM-related IPR&D.
- A $1.6 million non-cash gain from revaluing the EGEN earn-out liability partly offset expenses; the liability was $5.4 million at year-end. The company also recorded a $0.2 million loss on extinguishing the Horizon debt.
- Equity issuance provided $52.7 million net cash in 2021. The filing reports registered direct offerings of $35 million in January and $15 million in April, alongside at-the-market sales and warrant exercises. Common shares outstanding increased from about 2.7 million to 5.8 million on the filing’s reverse-split-adjusted basis.
Outlook, programs and risks
- GEN-1: In February 2022, the company reported 88 of 110 patients enrolled in OVATION 2. A prespecified safety review supported continued treatment at 100 mg/m², with no dose-limiting toxicities reported. Interim surgical data showed a 27% improvement in R0 resection rate for the treatment arm versus control among the first 39 patients undergoing surgery. The filing notes that no Phase II treatment-arm patient had yet received all 17 protocol doses; the primary endpoint is progression-free survival. Interim surgical results are not confirmatory efficacy evidence.
- ThermoDox: OPTIMA was stopped after the independent monitoring committee found the prespecified futility boundary crossed at the second interim analysis. The company ended survival follow-up in February 2021 after external analyses found no basis to continue. The earlier HEAT trial also failed its primary endpoint. ThermoDox activity continued in small investigator-sponsored studies, including Phase I studies in pancreatic and breast cancer.
- PLACCINE: 2021 mouse studies reported antibody and T-cell responses and neutralization in a cell assay. A non-human-primate challenge study was planned for 2022. The platform remained preclinical, and the filing describes proposed advantages rather than established clinical benefit.
- Capital and execution risks: The company had a $333 million accumulated deficit, no product revenue, and expected ongoing losses. Further equity or debt financing could be dilutive or unavailable on acceptable terms. Other material risks include clinical failure or delay, patient enrollment, reliance on third-party trial and manufacturing providers, regulatory uncertainty, competition, reimbursement, patent protection, and possible COVID-19 disruption.
- Subsequent events: In January 2022, the company raised approximately $28.5 million gross through Series A and B convertible redeemable preferred stock, then redeemed all of it for cash on March 3 at 105% of stated value. The redemption was approximately $31.5 million before any associated fees or expenses, so the financing should not be treated as a lasting $28.5 million liquidity increase. A 15-for-1 reverse split took effect for trading March 1, 2022; the company reported regaining Nasdaq’s minimum bid-price compliance.
- Contingencies and controls: The filing describes a securities class action, a derivative shareholder action and a books-and-records demand, each contested by the company; it did not provide a clear estimate of potential loss. Management concluded disclosure controls and internal control over financial reporting were effective at year-end. The auditor issued an unqualified opinion on the financial statements and identified goodwill, IPR&D and earn-out valuation as critical audit matters.
Important facts for investors to verify
- Confirm the issuer identity and corporate name change from Celsion to Imunon, and verify the current ticker and share count.
- Reconcile the reported $56.9 million liquidity measure to year-end cash, investments, restricted cash and NOL-sale proceeds; assess actual cash runway after the 2022 preferred-stock redemption and ongoing burn.
- Track OVATION 2 enrollment, completion of protocol dosing, safety updates and the prespecified progression-free-survival analysis; distinguish interim surgical data from the primary endpoint.
- Review the detailed OPTIMA results and the basis for discontinued follow-up, and treat historical subgroup analyses as retrospective rather than confirmatory.
- Assess the $5.4 million EGEN earn-out liability, the assumptions supporting the $13.4 million IPR&D valuation, debt covenants and maturities, and the status and possible financial effect of the pending litigation.